Liver Research最新文献

筛选
英文 中文
Expert consensus on liver transplantation perioperative evaluation and rehabilitation for acute-on-chronic liver failure 专家共识肝移植围手术期评估和康复治疗急性慢性肝衰竭
Liver Research Pub Date : 2022-09-01 DOI: 10.1016/j.livres.2022.08.002
Haijin Lv , Haiqing Zheng , Jianrong Liu , Qing Cai , Yuji Ren , Huimin Yi , Yang Yang , Xiquan Hu , Guihua Chen , Transplantation Immunology Committee of Branch of Organ Transplantation Physician of Chinese Medical Doctor Association, Organ Transplant Committee of China Association Rehabilitation Medicine, Guangdong Medical Doctor Association of Organ Transplantation
{"title":"Expert consensus on liver transplantation perioperative evaluation and rehabilitation for acute-on-chronic liver failure","authors":"Haijin Lv ,&nbsp;Haiqing Zheng ,&nbsp;Jianrong Liu ,&nbsp;Qing Cai ,&nbsp;Yuji Ren ,&nbsp;Huimin Yi ,&nbsp;Yang Yang ,&nbsp;Xiquan Hu ,&nbsp;Guihua Chen ,&nbsp;Transplantation Immunology Committee of Branch of Organ Transplantation Physician of Chinese Medical Doctor Association,&nbsp;Organ Transplant Committee of China Association Rehabilitation Medicine,&nbsp;Guangdong Medical Doctor Association of Organ Transplantation","doi":"10.1016/j.livres.2022.08.002","DOIUrl":"10.1016/j.livres.2022.08.002","url":null,"abstract":"<div><p>Acute-on-chronic liver failure (ACLF) can be cured by liver transplantation; however, perioperative complications still affect posttransplant outcomes. In recent years, early rehabilitation for critical illness, liver disease, and surgery have significantly improved organ reserve function, surgery tolerance, and postoperative quality of life. They could also be applied in the perioperative period of liver transplantation in patients with ACLF. Therefore, the Transplantation Immunology Committee of Branch of Organ Transplantation Physician of Chinese Medical Doctor Association, the Organ Transplant Committee of China Association Rehabilitation Medicine, and the Guangdong Medical Doctor Association of Organ Transplantation conducted a comprehensive review of rehabilitation in end-stage liver disease, critical illness and surgical patients by summarizing current evidence and best clinical practices and proposed a practice consensus on evaluation of cardiopulmonary and physical function, rehabilitation or physiotherapies, as well as the safety concerns in perioperative liver transplant recipients. It will be a valuable resource for hepatologists, transplant surgeons, and intensivists as they care for ACLF patients during transplantation.</p></div>","PeriodicalId":36741,"journal":{"name":"Liver Research","volume":"6 3","pages":"Pages 121-129"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542568422000381/pdfft?md5=2cfbc7609777731027494c7738f76764&pid=1-s2.0-S2542568422000381-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41780810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of roof plate-specific spondins in liver homeostasis and disease 顶板特异性反应蛋白在肝脏稳态和疾病中的作用
Liver Research Pub Date : 2022-09-01 DOI: 10.1016/j.livres.2022.09.002
Le Yang, Wenhui Yue, Hang Zhang, Yue Gao, Lin Yang, Liying Li
{"title":"The role of roof plate-specific spondins in liver homeostasis and disease","authors":"Le Yang,&nbsp;Wenhui Yue,&nbsp;Hang Zhang,&nbsp;Yue Gao,&nbsp;Lin Yang,&nbsp;Liying Li","doi":"10.1016/j.livres.2022.09.002","DOIUrl":"10.1016/j.livres.2022.09.002","url":null,"abstract":"<div><p>As evolutionarily conserved signals, roof plate-specific spondins (R-spondins; RSPOs) are a family with four members (RSPO1–4) exerting distinctly different functions. RSPOs have five receptors and correlate with different signaling pathways through these receptors and then perform various functions. Moreover, their best-known molecular function is the capacity to enhance WNT signaling pathways, which play critical roles in several processes. A recent study shows that RSPOs not only potentiate the WNT/beta (β)-catenin signaling pathway but are also involved in the WNT/planar cell polarity signaling pathway. RSPOs influence liver homeostasis and the development of multiple liver diseases. RSPO1 increases cell proliferation, protects hepatocytes from injury, improves liver regenerative potential, and affects liver metabolic zonation. RSPO2 not only regulates proliferation-associated genes and promotes differentiation in the liver but also participates in liver fibrosis through the WNT/β-catenin signaling pathway. RSPO3 is a key determinant of proper liver function, such as promoting hepatocyte regeneration and maintaining liver zonation. RSPO3 is upregulated in liver fibrosis and livers of patients with non-alcoholic steatohepatitis. Besides, RSPO2 and RSPO3 are confirmed as oncogenes and involved in the occurrence of liver cancer. The role of RSPO4 in the liver remains unclear. In this review, the structural and biochemical properties of RSPOs and their receptors and their roles in liver homeostasis and disease are summarized.</p></div>","PeriodicalId":36741,"journal":{"name":"Liver Research","volume":"6 3","pages":"Pages 139-145"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542568422000447/pdfft?md5=f7b452581758742b0a9960c19daf4db6&pid=1-s2.0-S2542568422000447-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48102479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exosomes as mediators of tumor immune escape and immunotherapy in hepatocellular carcinoma 外泌体作为肝癌肿瘤免疫逃逸和免疫治疗的介质
Liver Research Pub Date : 2022-09-01 DOI: 10.1016/j.livres.2022.08.001
Ming-Cheng Guan , Ming-Da Wang , Wan-Yin Wang , Chao Li , Lan-Qing Yao , Hong Zhu , Tian Yang
{"title":"Exosomes as mediators of tumor immune escape and immunotherapy in hepatocellular carcinoma","authors":"Ming-Cheng Guan ,&nbsp;Ming-Da Wang ,&nbsp;Wan-Yin Wang ,&nbsp;Chao Li ,&nbsp;Lan-Qing Yao ,&nbsp;Hong Zhu ,&nbsp;Tian Yang","doi":"10.1016/j.livres.2022.08.001","DOIUrl":"10.1016/j.livres.2022.08.001","url":null,"abstract":"<div><p>Hepatocellular carcinoma (HCC), a typical inflammatory-related cancer, mainly occurs in patients with chronic liver diseases. Moreover, the liver is an immunologically privileged apparatus with multiple immunosuppressive cell groups. The long process of inflammation-mediated carcinogenesis turns the HCC tumor microenvironment (TME) into one with strong immunosuppression, facilitating the immune escape of HCC cells. Accumulated data have manifested that tumor-associated cell-derived exosomes carry diverse molecular cargoes (<em>e.g.</em>, proteins and nucleic acids) for mediating cell-to-cell communication and are implicated in TME remodeling to promote tumor-infiltrating immune cell reprogramming, ultimately creating a tumor-friendly microenvironment. Characterized by several intrinsic attributes, such as good stability (bilayer-like structure) and high biocompatibility (cell secretion), exosomes can be modified or engineered as nanocarriers to deliver tumor-specific antigens or antitumor drugs to targeted cells or organs, thus effectively triggering the HCC cell elimination by the immune system. This review aimed to highlight the pivotal role of exosomes in regulating immune escape mechanisms in HCC and recent advances in exosome-mediated immunotherapy for HCC.</p></div>","PeriodicalId":36741,"journal":{"name":"Liver Research","volume":"6 3","pages":"Pages 132-138"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S254256842200037X/pdfft?md5=56a87450ba558ab2216462f86afcb8cd&pid=1-s2.0-S254256842200037X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41746433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Exhaled volatile organic compounds for cholangiocarcinoma diagnosis 呼出挥发性有机化合物用于胆管癌诊断
Liver Research Pub Date : 2022-09-01 DOI: 10.1016/j.livres.2022.09.001
Nanicha Siriwong , Thanikan Sukaram , Rossarin Tansawat , Terapap Apiparakoon , Thodsawit Tiyarattanachai , Sanparith Marukatat , Rungsun Rerknimitr , Roongruedee Chaiteerakij
{"title":"Exhaled volatile organic compounds for cholangiocarcinoma diagnosis","authors":"Nanicha Siriwong ,&nbsp;Thanikan Sukaram ,&nbsp;Rossarin Tansawat ,&nbsp;Terapap Apiparakoon ,&nbsp;Thodsawit Tiyarattanachai ,&nbsp;Sanparith Marukatat ,&nbsp;Rungsun Rerknimitr ,&nbsp;Roongruedee Chaiteerakij","doi":"10.1016/j.livres.2022.09.001","DOIUrl":"10.1016/j.livres.2022.09.001","url":null,"abstract":"<div><h3>Objectives</h3><p>The difficulties in the early detection consequent to the lack of sensitive biomarkers render patients with cholangiocarcinoma (CCA) to have poor outcomes. Recently, sensitive and specific volatile organic compounds (VOCs) were identified in several cancers. However, the VOC profiles in CCA are not well-studied. Thus, we investigated the VOC profiles in exhaled breath of CCA patients and controls.</p></div><div><h3>Methods</h3><p>We prospectively collected exhaled breath samples from 30 consecutive patients newly diagnosed with CCA and 30 controls who did not have CCA (seven had benign biliary strictures and 23 had other medical conditions). Exhaled VOCs were identified using gas chromatography mass spectrometry Triple Quadrupoles system. Analysis of the significant differences in VOCs between cases and controls was conducted using supervised multivariate regression analysis. Further validation was performed for these VOCs in another cohort of 18 CCA patients and 22 controls.</p></div><div><h3>Results</h3><p>Levels of six compounds were significantly different between CCA patients and controls, namely, acetone, isopropyl alcohol, dimethyl sulfide, 1,4-pentadiene, allyl methyl sulfide, and <em>N,N</em>-dimethylacetamide. Acetone and dimethyl sulfide were independently associated with CCA as demonstrated in the multivariate analysis. Using the cut-off value of 8.59 × 10<sup>7</sup> arbitrary unit (AU), acetone had a sensitivity and specificity of 82.1% and 75.8%, respectively, with an area under the receiving operator curve (AUROC) of 0.85 for the CCA diagnosis. Acetone level was also significantly different between cases and controls in the validation cohort. Using the same cut-off value, the sensitivity, specificity, and AUROC was 59.1%, 66.7%, and 0.85, respectively.</p></div><div><h3>Conclusion</h3><p>Breath analysis may potentially be useful for CCA diagnosis. A cohort of patients with early-stage CCA in further studies is needed to confirm the ability of exhaled VOCs for the early detection of CCA.</p></div>","PeriodicalId":36741,"journal":{"name":"Liver Research","volume":"6 3","pages":"Pages 191-197"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542568422000435/pdfft?md5=ffa93ddf42c1042e4779186f13e8c5e6&pid=1-s2.0-S2542568422000435-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46397788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Telehealth interventions for alcohol use disorder: A systematic review 远程医疗干预酒精使用障碍:系统综述
Liver Research Pub Date : 2022-09-01 DOI: 10.1016/j.livres.2022.08.004
Arpad Kelemen , Elizabeth Minarcik , Christopher Steets , Yulan Liang
{"title":"Telehealth interventions for alcohol use disorder: A systematic review","authors":"Arpad Kelemen ,&nbsp;Elizabeth Minarcik ,&nbsp;Christopher Steets ,&nbsp;Yulan Liang","doi":"10.1016/j.livres.2022.08.004","DOIUrl":"10.1016/j.livres.2022.08.004","url":null,"abstract":"<div><p>Alcohol use disorder (AUD) is a worldwide problem for individuals of varying ages and backgrounds and is associated with the underlying cause of alcoholic liver disease, liver cirrhosis, liver cancer, or many other common diseases and health conditions. Existing treatments such as cognitive behavioral therapy (CBT) have been demonstrated as an evidence-based treatment to aid individuals struggling with AUD. However, these treatments have excessive costs and time demand with trained experts. In this paper, we examine the efficacy and long-term impacts of digitally delivered CBT and other online telehealth tools and apps for AUD patients. Results show the effectiveness in the ability of digitally delivered CBT to decrease alcohol use in AUD patients. The additional use of online technologies and smartphone apps for post-CBT care demonstrates that such computer-aided apps could have long-term effects when it is continually employed, which opens the door for AUD patients who were not seeking treatment elsewhere. Further longitudinal examination research is needed to evaluate the lasting effects in liver health and other chronic diseases associated with digitally delivered alcohol reduction for AUD patients.</p></div>","PeriodicalId":36741,"journal":{"name":"Liver Research","volume":"6 3","pages":"Pages 146-154"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S254256842200040X/pdfft?md5=8fbce689a33ddc23b39dd3cc667c3552&pid=1-s2.0-S254256842200040X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41252522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Dynactin 2 acts as an oncogene in hepatocellular carcinoma through promoting cell cycle progression Dynactin 2通过促进细胞周期进展在肝细胞癌中发挥致癌基因作用
Liver Research Pub Date : 2022-09-01 DOI: 10.1016/j.livres.2022.07.002
Wenchao Li , Jiehuan Chen , Zhiyong Xiong , Hui Zhou , Shaozhuo Huang , Jie Ren , Bo Liu , Taicheng Zhou , Kunpeng Hu
{"title":"Dynactin 2 acts as an oncogene in hepatocellular carcinoma through promoting cell cycle progression","authors":"Wenchao Li ,&nbsp;Jiehuan Chen ,&nbsp;Zhiyong Xiong ,&nbsp;Hui Zhou ,&nbsp;Shaozhuo Huang ,&nbsp;Jie Ren ,&nbsp;Bo Liu ,&nbsp;Taicheng Zhou ,&nbsp;Kunpeng Hu","doi":"10.1016/j.livres.2022.07.002","DOIUrl":"10.1016/j.livres.2022.07.002","url":null,"abstract":"<div><h3>Background</h3><p>Dynactin (DCTN) can activate cytoplasmic dynein and drive intracellular organelle transport containing six family members (DCTN1 to DCTN6). The DCTN family has been studied as cancer-related genes or biomarkers in various cancers. Nevertheless, in hepatocellular carcinoma (HCC), the functions and prognostic roles of the DCTN family have been unexplored.</p></div><div><h3>Methods</h3><p>We evaluated the diagnostic and survival effects of DCTN subunits in HCC through bioinformatics analysis and validated the results of bioinformatics by our data to address this problem.</p></div><div><h3>Results</h3><p>The results of bioinformatics analysis found that DCTN2 was a significant prognostic factor in HCC, and high-level DCTN2 can predict poor patient survival in HCC. Cox regression analysis also suggested that DCTN2 (hazard ratio = 1.748, 95% confidence interval 1.190–2.568, <em>P</em> = 0.004) is an independent prognostic factor for patient survival. Western blot and quantitative reverse transcription-polymerase chain reaction assays confirmed that the protein and mRNA expression levels of DCTN2 were upregulated in HCC cell lines. The proliferation, invasion, and migration were decreased and cell apoptosis was enhanced after DCTN2 was knocked down in Huh7 and Hep3B cells. DCTN2 promoted the cell cycle progression through regulating the expression of cell cycle regulatory proteins cyclin-dependent kinase 4, Cyclin D1, and p21.</p></div><div><h3>Conclusions</h3><p>We propose that DCTN2 can serve as a prognostic marker for HCC. DCTN2 acts as an oncogene and promotes the cell cycle progression through the G1/S phase-related signaling pathway.</p></div>","PeriodicalId":36741,"journal":{"name":"Liver Research","volume":"6 3","pages":"Pages 155-166"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542568422000368/pdfft?md5=31044a9f9a9063c8e81dd5393b6735ee&pid=1-s2.0-S2542568422000368-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46739346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Glycogen accumulation drives hepatocarcinogenesis by targeting the Hippo signaling pathway 糖原积累通过靶向Hippo信号通路驱动肝癌发生
Liver Research Pub Date : 2022-09-01 DOI: 10.1016/j.livres.2022.07.001
Weicheng Liang , Qi Zhang
{"title":"Glycogen accumulation drives hepatocarcinogenesis by targeting the Hippo signaling pathway","authors":"Weicheng Liang ,&nbsp;Qi Zhang","doi":"10.1016/j.livres.2022.07.001","DOIUrl":"10.1016/j.livres.2022.07.001","url":null,"abstract":"","PeriodicalId":36741,"journal":{"name":"Liver Research","volume":"6 3","pages":"Pages 198-200"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542568422000356/pdfft?md5=60be87212881ce484d954f8ec9fa8f0b&pid=1-s2.0-S2542568422000356-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44362564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The S267F variant of sodium taurocholate co-transporting polypeptide is strongly associated with resistance to chronic hepatitis B and high level of serum total bile acids 牛磺酸胆酸钠共转运多肽的S267F变异与慢性乙型肝炎的耐药性和血清总胆汁酸的高水平密切相关
Liver Research Pub Date : 2022-09-01 DOI: 10.1016/j.livres.2022.08.005
Jiancheng Huang , Mingkuan Su , Hongbin Chen , Shuiqing Wu , Zongyun Chen
{"title":"The S267F variant of sodium taurocholate co-transporting polypeptide is strongly associated with resistance to chronic hepatitis B and high level of serum total bile acids","authors":"Jiancheng Huang ,&nbsp;Mingkuan Su ,&nbsp;Hongbin Chen ,&nbsp;Shuiqing Wu ,&nbsp;Zongyun Chen","doi":"10.1016/j.livres.2022.08.005","DOIUrl":"10.1016/j.livres.2022.08.005","url":null,"abstract":"<div><h3>Background and aims</h3><p>The sodium taurocholate co-transporting polypeptide (NTCP) is a functional receptor for the hepatitis B virus (HBV), and it is critical for bile acid homeostasis. Previous studies of the association between the S267F variant and chronic hepatitis B (CHB) have generated conflicting results. This study analyzed the correlation between the <em>NTCP</em> S267F variant and CHB susceptibility by using a large sample of participants classified by gender and age, and this study also analyzed the relationship between this variant and the level of serum total bile acids.</p></div><div><h3>Methods</h3><p>In total, 543 patients with CHB and 429 control subjects underwent S267F variant genotyping using SNaPshot technology. Logistic regression was utilized to evaluate any association of the <em>NTCP</em> S267F variant with CHB susceptibility.</p></div><div><h3>Results</h3><p>The S267F variant was inversely correlated with the risk of chronic HBV infection in both the dominant model (<em>GG</em> genotype <em>vs. AG</em> genotype: odds ratio (OR) = 0.46, 95% confidence interval (CI) 0.30–0.71, <em>P</em> &lt; 0.001) and the allele model (<em>G</em> allele <em>vs. A</em> allele: OR = 0.50, 95% CI 0.33–0.76, <em>P</em> = 0.001), and this correlation was not affected by gender and age stratification. The carriers of the heterozygous <em>NTCP</em> variant exhibited higher total bile acids levels than the carriers of wild-type <em>NTCP</em>, regardless of whether they were control subjects or patients with CHB. Heterozygous carriers exhibited reduced hepatitis B e antigen (HBeAg)-positivity rates and had lower ALT, AST, and lg DNA concentrations compared with wild-type carriers in patients with CHB.</p></div><div><h3>Conclusions</h3><p>The S267F variant of <em>NTCP</em> is a protective factor that reduces the risk of chronic HBV infection and exhibits a higher total bile acids level. Patients with CHB who carry this variant may have a better prognosis than those carrying wild-type <em>NTCP</em>.</p></div>","PeriodicalId":36741,"journal":{"name":"Liver Research","volume":"6 3","pages":"Pages 186-190"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542568422000411/pdfft?md5=67a779d4c3426d8a3549af6c611d0502&pid=1-s2.0-S2542568422000411-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45537974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of intestine-specific deletion of fibroblast growth factor 15 on alcoholic liver disease development in mice 肠特异性缺失成纤维细胞生长因子15对小鼠酒精性肝病发展的影响
Liver Research Pub Date : 2022-06-01 DOI: 10.1016/j.livres.2022.05.001
Bo Kong , Mingxing Huang , Rulaiha E. Taylor , Daniel Rizzolo , Katherine D. Otersen , Grace L. Guo
{"title":"Effects of intestine-specific deletion of fibroblast growth factor 15 on alcoholic liver disease development in mice","authors":"Bo Kong ,&nbsp;Mingxing Huang ,&nbsp;Rulaiha E. Taylor ,&nbsp;Daniel Rizzolo ,&nbsp;Katherine D. Otersen ,&nbsp;Grace L. Guo","doi":"10.1016/j.livres.2022.05.001","DOIUrl":"10.1016/j.livres.2022.05.001","url":null,"abstract":"<div><h3>Background and aims</h3><p>Alcoholic liver disease (ALD) is an important and growing cause for the development of chronic liver diseases in the world. Bile acid (BA) levels are increased in patients with ALD and dysregulation of BA homeostasis worsens ALD. BA synthesis is critically regulated by fibroblast growth factor (FGF)15 in mice and FGF19 in humans. FGF15/19 are mainly produced in the ileum and their main function is to suppress BA synthesis in the liver through the activation of fibroblast growth factor receptor 4 (FGFR4) on hepatocytes. The effects of intestine-specific <em>Fgf15</em> deficiency on the development of ALD were determined in the current study.</p></div><div><h3>Methods</h3><p>Enterocyte-specific <em>Fgf15</em> knockout mice (<em>Fgf15</em><sup><em>int−/−</em></sup>) and the established mouse model by chronic and binge ethanol feeding (NIAAA model) were adapted in this study.</p></div><div><h3>Results</h3><p>The <em>Fgf15</em><sup><em>int−/−</em></sup> mice had increased BA pool size, consistent with negative effects of FGF15-FGFR4 signaling on BA synthesis. There were not obviously physical and hepatic histological abnormalities presented in <em>Fgf15</em><sup><em>int−/−</em></sup> mice compared to wild-type mice. Following alcohol treatment, the <em>Fgf15</em><sup><em>int−/−</em></sup> mice exhibited a higher degree of liver injury, increased hepatic expression of <em>Cd14</em>, a receptor for lipopolysaccharide expressed in the liver, and increased hepatic lipid levels. We did not observe alterations in the levels of fibrosis in the liver or expression of genes involved in hepatic fibrosis, regardless of genotypes or following the alcohol treatment.</p></div><div><h3>Conclusions</h3><p>FGF15 may prevent hepatic steatosis in the development of ALD in mice, and maintaining FGF19/FGFR4 signaling may be critical in the prevention and/or treatment of ALD in humans in the future.</p></div>","PeriodicalId":36741,"journal":{"name":"Liver Research","volume":"6 2","pages":"Pages 84-92"},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542568422000198/pdfft?md5=775b328c16bf427dd7cbf8231e773490&pid=1-s2.0-S2542568422000198-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44337034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Camrelizumab (SHR-1210) treatment for recurrent hepatocellular carcinoma after liver transplant: A report of two cases Camrelizumab (SHR-1210)治疗肝移植后复发性肝癌2例报告
Liver Research Pub Date : 2022-06-01 DOI: 10.1016/j.livres.2021.06.002
Tianxing Dai , Qing Yang , Yingcai Zhang , Linsen Ye , Hua Li , Shuhong Yi , Wei Liu , Yang Yang , Guoying Wang
{"title":"Camrelizumab (SHR-1210) treatment for recurrent hepatocellular carcinoma after liver transplant: A report of two cases","authors":"Tianxing Dai ,&nbsp;Qing Yang ,&nbsp;Yingcai Zhang ,&nbsp;Linsen Ye ,&nbsp;Hua Li ,&nbsp;Shuhong Yi ,&nbsp;Wei Liu ,&nbsp;Yang Yang ,&nbsp;Guoying Wang","doi":"10.1016/j.livres.2021.06.002","DOIUrl":"10.1016/j.livres.2021.06.002","url":null,"abstract":"<div><p>Immune checkpoint inhibitors are generally contraindicated for post-transplant patients. However, we report two patients with metastatic hepatocellular carcinoma (HCC) treated with camrelizumab (SHR-1210), an anti-programmed cell death 1 (PD-1) agent, after liver transplant. Before undergoing immunotherapy, both patients underwent liver allograft biopsy and obtained negative PD-L1 expression in tumor and liver graft specimens by immunohistochemistry. Then, camrelizumab (200 mg) was administered once every 3 weeks. During immunotherapy, the targeted therapy was continued, and the immunosuppression regimen was adjusted to a low-dose level. No graft rejection or other severe adverse reactions were observed. The disease remained stable (SD, mRECIST) for 3 months in one patient and 10 months in the other. Therefore, camrelizumab may have safety and potential benefits in advanced HCC after liver transplant.</p></div>","PeriodicalId":36741,"journal":{"name":"Liver Research","volume":"6 2","pages":"Pages 111-115"},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.livres.2021.06.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"55273515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信